Table 2 Different drug loading into EVs for cancer therapy
From: Extracellular Vesicles for Drug Delivery in Cancer Treatment
Cargo | Years | Source of EVs | Cancer type |
|---|---|---|---|
Doxorubicin | 2015 | THP-1 macrophages | Ovarian and prostate cancer therapy |
2019 | Pancreatic cancer cells, pancreatic stellate cells, and macrophages | Pancreatic cancer treatment | |
2015 | MCF-7 cells | Breast cancer therapy | |
2019 | MSC | Osteosarcoma therapy | |
2013 | Mouse immature dendritic cells (imDCs) | Breast cancer therapy | |
2019 | HEK293 cell | Breast cancer therapy | |
2019 | MDA-MB-231 cells | Cervical cancer therapy | |
Paclitaxel | 2014 | Murine SR4987 cells | Ductal pancreatic adenocarcinoma therapy |
2017 | Bone marrow mesenchymal stromal cells (BM-MSCs) | Myeloma therapy | |
2017 | Canine mesenchymal stromal cells (cMSCs) | Glioblastoma treatment | |
2016 | RAW 264.7 macrophages | Lewis lung carcinoma therapy | |
2017 | Bovine milk | Lung cancer therapy | |
2015 | LNCaP and PC-3 PCa cell lines | Prostate cancer treatment | |
2019 | U-87 cells | Glioblastoma therapy | |
Gemcitabine | 2020 | Pancreatic cancer therapy | Pancreatic cancer therapy |
2020 | M1 Macrophages | Chemoresistant pancreatic cancer treatment | |
2020 | Panc-1 cells | Pancreatic cancer therapy | |
Paclitaxel, Doxorubicin and Gemcitabine | 2017 | GinPa-MSCs | Oral squamous cell carcinoma therapy |
Paclitaxel and doxorubicin | 2015 | Brain endothelial bEND.3 cells | Brain cancer therapy |
2020 | RAW 264.7 macrophages | Triple negative breast cancer therapy | |
Withaferin A, anthocyanidins, curcumin, paclitaxel and docetaxel | 2015 | Bovine milk | Lung cancer therapy |
Methotrexate and cisplatin | 2012 | A2780 human ovarian cancer cell | Hepatocarcinoma and ovarian cancer treatment |
Methotrexate | 2018 | L929 cells | Glioblastoma treatment |